GlassScriptPhysician profile
Omar Hamze
NPI 1437148293
$89,975.23
in general payments reported to CMS, 2019-2025
32 companies · $3,613 in 2025
The $3,613 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,087 · 2020: $3,848 · 2021: $16K · 2022: $27K · 2023: $18K · 2024: $15K · 2025: $3,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $6,474 · Honoraria: $5,600 · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,145.50 |
| Food and Beverage | $6,473.82 |
| Honoraria | $5,600.00 |
| Education | $388.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30,372.85 | 2019-2024 | Farxiga, Lokelma, Evusheld |
| Fresenius USA Marketing, INC. | $17,207.76 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $14,814.20 | 2022-2025 | |
| Vifor Pharma, INC. | $9,019.77 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $6,858.57 | 2019-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,248.46 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $2,334.14 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $1,151.80 | 2021-2025 | Lupkynis |
| Amgen INC. | $1,067.57 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $819.81 | 2022-2025 | Filspari |
| Ardelyx, INC. | $555.85 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $478.97 | 2021-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $306.19 | 2022-2025 | Tarpeyo |
| Medtronic, INC. | $250.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $238.06 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $155.90 | 2021-2023 | Benlysta |
| Nxstage Medical, INC. | $134.66 | 2022 | |
| Bard Peripheral Vascular, INC. | $118.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $118.81 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $95.89 | 2019 | |
| Recor Medical INC | $92.73 | 2025 | Paradise Ultrasound Renal Denervation System |
| Vantive US Healthcare LLC | $76.83 | 2025 | Renal - Pd |
| Horizon Therapeutics Plc | $68.82 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $63.15 | 2020-2025 | Terlivaz |
| Akebia Therapeutics INC | $54.96 | 2020-2024 | Vafseo, Auryxia |
| Shield Therapeutics INC | $53.48 | 2024 | |
| Cormedix INC. | $52.83 | 2024 | Defencath |
| Genzyme Corporation | $47.06 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $40.44 | 2022 | |
| Mallinckrodt Enterprises LLC | $34.46 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.37 | 2019-2021 | |
| Abbvie INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Hamze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.